Skip to main content
OpenTrials

Clinical trial condition

B-cell Lymphoma

Explore clinical trials studying B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

83 public trials 22 recruiting studies
Refine in advanced search Browse all conditions

B-cell Lymphoma trial results

Completed

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

NCT02741388

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Institut Jules Bordet Brussels, Belgium
  • CHU Dijon Dijon, France
  • CHRU de Lille - Hôpital Claude Huriez Lille, France
  • CHU Montpellier - Hôpital Saint Eloi Montpellier, France
View Trial Details
Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

NCT02933320

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +22 more
Locations
  • Leicester Royal Infirmary Leicester, England, United Kingdom
  • Christie Hospital Manchester, England, United Kingdom
  • Oxford Cancer and Haematology Centre, Churchill Hospital Oxford, England, United Kingdom
  • Derriford Hospital Plymouth, United Kingdom
View Trial Details
Completed

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

NCT02900716

Conditions
B-cell Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +18 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

A Study for Patients With Non-Hodgkin's Lymphomas

NCT00542919

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Anaheim, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Garran, Australian Capital Territory, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gosford, New South Wales, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Auchenflower, Queensland, Australia
View all 14 locations
View Trial Details
Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

NCT02945215

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Beijing cancer hospital Beijing, Beijing Municipality, China
  • Peking University third hospital Beijing, Beijing Municipality, China
  • The 307th Hospital of Military Medical Sciences Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Haerbin, Heilongjiang, China
View Trial Details
Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +33 more
Locations
  • University of California at Los Angeles Los Angeles, California, United States
  • Stanford University School of Medicine Stanford, California, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • University of Chicago Hospital Chicago, Illinois, United States
View all 15 locations
View Trial Details
Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

NCT01980628

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Site Reference ID/Investigator# 837 Tucson, Arizona, United States
  • Site Reference ID/Investigator# 047 Duarte, California, United States
  • Site Reference ID/Investigator# 377 Santa Monica, California, United States
  • Site Reference ID/Investigator# 763 West Palm Beach, Florida, United States
View all 25 locations
View Trial Details

Related conditions